ESTRO 2021 Abstract Book

S1186

ESTRO 2021

.

Conclusion Spine SBRT results in high LC rates and durable progression-free survival with modest incidence of mild toxicity. A better knowledge of determinants of radioresistance (both intrinsically inherent to tumor biology or acquired following repeated administration of systemic therapy) is desirable due to potential correlation with impaired LC. A controlled primary site is associated with longer time to further distant progression following SBRT, supporting local treatment of primary tumor in selected metastatic patients. PO-1445 Pediatric palliative radiotherapy: a systematic review L. Ronchi 1 , C.M. Donati 2 , C.M. Donati 3 , M.C. Mondardini 4 , A. Prete 5 , M.L. Alfieri 1,6 , B. Rombi 7 , F. Bertini 1,8 , M. Buwenge 9 , A.G. Morganti 10,1 , S. Cammelli 2,6 1 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna , Italy; 2 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3 Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Alma Mater Studiorum Bologna University; Bologna, Italy, Bologna , Italy; 4 Pediatric Intensive Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 5 Pediatric Hematology-Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna , Italy; 6 Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Alma Mater Studiorum Bologna University, Bologna , Italy; 7 Proton Therapy Center, Santa Chiara Hospital, Trento, Italy; 8 Department of Experimental, Diagnostic, and Specialty Medicine , DIMES, Alma Mater Studiorum Bologna University, Bologna , Italy; 9 Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Alma Mater Studiorum Bologna University, Bologna , Italy; 10 Department of Experimental, Diagnostic, and Specialty Medicine , DIMES, Alma Mater Studiorum Bologna University, Bologna, Italy Purpose or Objective Pediatric Palliative Radiotherapy (PPR) is an effective option to relieve symptoms due to progressive or metastatic disease. Aim to this work is to systematically review the literature on PPR available. Materials and Methods A systematic review based on PRISMA methodology was conducted in order to identify studies on PPR. A database search on Pubmed of papers published from 1st January 2000 through 01st March 2021 was carried out. Only articles published in English were considered. Studies on RT combined with concurrent or sequential chemotherapy with single or multiple agents, new target agents therapies and/or surgery were included. Case series, editorials and reviews were excluded. The primary outcome was symptomatic response while the secondary end-points was toxicity. Results One hundred and forty-one papers were identified through Pubmed database searching. After the screening process, 10 papers met the inclusion criteria and were considered for this analysis. All studies were retrospective. The total number of included patients was 1.152. In all studies the median patients age was < 18 years (range 6.0-17.9). Most frequent indication to PPR were pain, dyspnea, and neurological symptoms. Eight out of 10 papers reported on symptoms relieve with percentage ranging between 86% and 44% with a mean value of 68.4%. Two out of 10 paper did not report toxicity. Eight studies reported toxicity outcomes of whom five reported toxicities ≥ Gr.3 with percentage ranging between 0.3% and 6.7% (the highest percentage, were described in patients receiving concurrent chemotherapy and/or re-irradiation).